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Objectives The PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) prospective registry was designed to assess
the predictive accuracy of sustained ventricular tachycardia/ventricular fibrillation (VTs/VF) inducibility and to
identify additional predictors of arrhythmic events in Brugada syndrome patients without history of VT/VF.
Background Brugada syndrome is a genetic disease associated with increased risk of sudden cardiac death. Even though its value
has been questioned, inducibility of VTs/VF is widely used to select candidates to receive a prophylactic implantable
defibrillator, and its accuracy has never been addressed in prospective studies with homogeneous enrolling criteria.
Methods Patients with a spontaneous or drug-induced type I electrocardiogram (ECG) and without history of cardiac arrest were en-
rolled. The registry included 308 consecutive individuals (247men, 80%; median age 44 years, range 18 to 72 years). Pro-
grammed electrical stimulation was performed at enrollment, and patients were followed-up every 6 months.
Results During a median follow-up of 34 months, 14 arrhythmic events (4.5%) occurred (13 appropriate shocks of the
implantable defibrillator, and 1 cardiac arrest). Programmed electrical stimulation performed with a uniform and
pre-specified protocol induced ventricular tachyarrhythmias in 40% of patients: arrhythmia inducibility was not a
predictor of events at follow-up (9 of 14 events occurred in noninducible patients). History of syncope and spon-
taneous type I ECG (hazard ratio [HR]: 4.20), ventricular refractory period 200 ms (HR: 3.91), and QRS frag-
mentation (HR: 4.94) were significant predictors of arrhythmias.
Conclusions Our data show that VT/VF inducibility is unable to identify high-risk patients, whereas the presence of a sponta-
neous type I ECG, history of syncope, ventricular effective refractory period 200 ms, and QRS fragmentation
seem useful to identify candidates for prophylactic implantable cardioverter defibrillator. (J Am Coll Cardiol
2012;59:37–45) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.064a
SBrugada syndrome (BrS) was described in 1992 as a disease
that predisposes apparently healthy individuals to sudden
cardiac death (1). Patients present with a typical electrocar-
diographic pattern characterized by a coved type ST-
segment elevation in the right precordial leads (V1 to V3)
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uch a diagnostic electrocardiographic profile might be
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or it might be concealed and
unmasked upon intravenous ad-
ministration of sodium channel
blockers (Fig. 1B) such as fle-
cainide, ajmaline, procainamide,
or pilsicainide (2). This diagnos-
tic electrocardiographic pattern
has a worldwide prevalence in
the general population of 1 of
1,000 individuals (3), represent-
ing a relevant health care issue.
Although quinidine was pro-
posed as a possible pharmaco-
logic therapy to abate the risk of
life-threatening arrhythmias (4),
controlled clinical trials that con-
firm its effectiveness are lacking.
Therefore, clinicians are left with the challenging task to
select patients who might benefit from an implantable
defibrillator.
Pedro and Josep Brugada were the first to propose in
2002, on the basis of data from their registry, that sustained
ventricular tachycardia/ventricular fibrillation (VTs/VF) in-
Abbreviations
and Acronyms
BrS  Brugada syndrome
CI  confidence interval
ECG  electrocardiogram
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
PES  programmed
electrical stimulation
QRS-f  QRS fragmentation
VRP  ventricular
refractory period
VTs/VF  sustained
ventricular tachycardia/
ventricular fibrillation
Figure 1 ECG Presentation in Brugada Syndrome
Examples of electrocardiographic (ECG) traces (A to C). (A) A 35-year-old male pa
with type III ECG (left panel) converted to type I after 2 mg/l intravenous Flecainid
tion presenting with QRS fragmentation at enrollment; arrows indicate the QRS pe
ventricular fibrillation in a PRELUDE (PRogrammed ELectrical stimUlation preDictiveducibility at programmed electrical stimulation (PES) is
useful to identify patients at high risk of sudden death (5).
In the same year we were unable to confirm the predictive
value of the test in our BrS cohort, and we suggested that
the use of PES might lead to the unnecessary insertion of an
implantable cardioverter-defibrillator (ICD) due to the high
inducibility rate (6). Our data showed the presence of a
spontaneous type I electrocardiogram (ECG) and the his-
tory of syncope were the only predictors of adverse outcome;
accordingly, we proposed a risk stratification scheme that
recommends ICD only in the patients with a spontaneous
ST-segment elevation and history of syncope.
To sort out the debate on the value of VTs/VF induc-
ibility, a group of experienced investigators convened to
discuss the matter and produced a consensus document to
support the use of VTs/VF inducibility to identify high-risk
patients who should be treated with a defibrillator (7). As a
result, VTs/VF inducibility became largely adopted to guide
the management of patients. Over the years, in agreement
with our initial report, other studies failed to confirm the
capability of VTs/VF inducibility to identify high-risk
individuals (8). Subsequent data from Brugada et al. con-
firmed its value (9–11), whereas in 2005 the second con-
sensus conference (9) issued a Class IIa for use of PES in
ith presenting spontaneous type I ECG; (B) 30-year-old male patient presenting
t panel). (C) V1 and V2 leads of 2 patients with spontaneous ST-segment eleva-
alibration bars 10 mV/400 ms); (D) implantable cardioverter-defibrillator–stored
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PES in patients without a spontaneous type I pattern. In
2006 the American Heart Association/American College of
Cardiology/European Society of Cardiology guidelines for
prevention of sudden death (12) reflected the ongoing
debate and did not provide stringent indication for PES in
BrS (Class IIb).
Today, after almost 1 decade, the field is still struggling
with the discordant results derived from retrospective anal-
ysis of different registries (13–15), and clinicians often still
use PES to identify patients in need of an ICD.
To contribute to fill this gap, we organized an Italian multi-
center prospective registry called PRELUDE (PRogrammed
ELectrical stimUlation preDictive valuE) to assess the role
of PES and VTs/VF inducibility in patients with BrS in
whom there was no history of sustained ventricular tachy-
cardia or ventricular fibrillation. Enrollment of patients
was open to all Italian electrophysiology centers willing to
participate. The study was endorsed by the Italian Cardiac
Arrhythmias Association (Associazione Italiana Aritmolo-
gia e Cardiostimolazione).
Objectives of the PRELUDE registry were: 1) to evaluate
the impact of different protocols of ventricular inducibility
on the predictive value of PES; 2) to evaluate prospectively
the predictive value of PES; and 3) to search for novel
outcome predictors in BrS.
Methods
Registry design and enrollment criteria. The study was
coordinated by the team at the Maugeri Foundation in Pavia;
the participating centers are listed in the acknowledgments,
and the top 10 enrolling centers coauthored the study.
Patients were considered eligible if they were older than
18 years, presented either a spontaneous or a pharmacolog-
ically induced type I ECG pattern with coved ST-segment
elevation2 mm in at least 2 right precordial leads, and had
never experienced either cardiac arrest or sustained ventric-
ular tachycardia (7), because this latter group of patients
already has a Class I indication for ICD insertion (12). At
the time of enrollment an ECG was sent to the coordinat-
ing center to validate the presence of a type I ECG and
ensure the presence of uniform enrollment criteria in the
study population. At enrollment, 2 blinded investigators
(C.N., S.G.P.) assessed the following parameters: PR in-
terval, QRS, presence of complete right bundle branch
block, QT, corrected QT, and QRS fragmentation (QRS-f)
(16) defined as 2 or more spikes within the QRS complex in
leads V1 to V3 (Fig. 1C).
The absence of structural cardiac abnormalities or cardiac
iseases (such as previous myocardial infarction, cardiomyop-
thies, angina, or left ventricular hypertrophy) was verified
efore enrollment by echocardiography and exercise stress test.
All patients underwent PES to assess VTs/VF inducibility.
t the present time, there is no agreement on how PES should
e performed in BrS, and the American College of Cardiology/ Pmerican Heart Association/European Society of Cardiol-
gy guidelines for prevention of sudden cardiac death did
ot recommend any specific protocol (12). In the absence of
uidance, the PRELUDE investigators agreed on a stimu-
ation protocol consisting of 2 drive cycles (600 and 400 ms,
1) and 3 extrastimuli (S2 to S4) according to the protocol
eported by Brugada et al. (17,18). Minimum coupling
nterval of premature beats was set to 200 ms for S2 and S3
nd to refractoriness for S4. The inducibility protocol was
erformed from the apex of the right ventricle and from the
ight ventricular outflow tract unless the patient had induc-
ble ventricular tachycardia at the first location (9).
“Inducible patients” were defined as those in whom PES
nduced ventricular fibrillation, sustained polymorphic ven-
ricular tachycardia (30 s of duration), or polymorphic
yncopal ventricular tachycardia requiring direct current
hock. This definition closely follows that of Brugada et al. (5).
henever the physician elected to assess short-term reproduc-
bility of PES, the inducibility protocol was repeated in the
nducible patients. The test was considered reproducible (i.e.,
onfirmatory of the result obtained in the first test) when
Ts/VF was induced a second time with the same protocol.
easurements of the ventricular refractory period (VRP) (19)
delivery of an S2 at twice the diastolic threshold on a driving
ycle of 600 ms with a minimal coupling interval of 200 ms
rom the apex) were also collected; for the purpose of the
nalysis, when conduction of the S2 at 200 ms was preserved,
t was inferred that VRP was 200 ms.
Enrollment of patients in the PRELUDE registry did not
nfluence therapeutic strategies: physicians were free to
hoose with their patients the preferred management op-
ion. Similarly, the physicians and patients were free to
ecide whether genetic testing should be performed.
Personal history of syncopal spell and family history of
rS or unexplained sudden cardiac death were collected.
yncope was defined as an abrupt loss of consciousness
ccurring at rest or a loss of consciousness during sleep with
gonal respiration reported by bystanders. The first
ollow-up visit for patients who received an ICD was
cheduled 3 months after surgery.
“Arrhythmic events” at follow-up were defined as the
ccurrence of ventricular fibrillation or appropriate ICD inter-
entions on the basis of the clinical judgment of the cardiolo-
ist in charge of the patient. Documentation of ICD shocks
as collected by the coordinating center at the Maugeri
oundation.
Follow-up visits were scheduled every 6 months. Data entry
as performed at each center on a web-based case report form;
ach patient was attributed an anonymous code, and no
ersonal data/identifiers were part of the case report form.
nly physicians in charge of patients were able to retrieve the
dentity of patients. The ethics committee of each participating
enter approved the study protocol and the informed consent
or patients. Separate institutional review board-approved con-
ent forms were used for genetic testing. Enrollment in the
RELUDE registry started in July 2004 and ended in March
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and the dataset was closed on March 2010.
Statistical analysis. Data are reported as mean  SD and
ere analyzed with SPSS statistical package (version 17.0,
PSS, Chicago, Illinois). Mean comparisons were per-
ormed with unpaired t test. Frequencies were compared
ith cross-tab with chi-square; Fisher test was applied as
ppropriate. Significance was defined for p values 0.05. A
ost-hoc power analysis showed a power  0.8 with effect
ize w  0.16 to detect PES efficacy in our population
Online Appendix). The cumulative probability of a first
rrhythmic event at follow-up was determined with the life-
able method of Kaplan and Meier for the entire population
nd for different sub-groups. Log-rank test was applied.
nducibility was tested versus each covariate with Cox multi-
ariate survivorship analysis to evaluate the significance and
ndependence of predictors of a first arrhythmic event at
ollow-up, and hazard ratios (HRs) were calculated. We ran 2
eparate models, first with inducibility versus each of the other
ovariates, then with inducibility with all other covariates together
Demographic Data of the PRELUDE Cohort (N  308)Table 1 Demographic Data of the PRELUDE Cohort (N  308)
Age at enrollment (yrs) 47 12
Male 247 (80)
Spontaneous type 1 ECG 171 (56)
VTs/VF inducibility, n inducible (%) 126 (41)
First-degree AV block 52 (17)
QRS duration (ms) 101 14
Complete RBBB 29 (9.4)
QRS-f 25 (8.1)
VRP (ms) 198 27
Annual event rate 1.5%
Values are mean  SD or n (%).
AV  atrioventricular; ECG  electrocardiogram; RBBB  right bundle branch block; PES 
programmed electrical stimulation; PRELUDE  PRogrammed ELectrical stimUlation preDictive
aluE registry; QRS-f  fragmented QRS (see text for explanation); VRP  ventricular refractory
eriod; VTs/VF  sustained ventricular tachycardia/ventricular fibrillation.
Patients With Events at Follow-UpTable 2 Patients With Events at Follow-Up
Patient ID # Sex
Age
(yrs)*
Family History
of SCD
Spontaneous
Type 1 ECG
His
Sy
4 M 43  
10 M 35  
174 M 69  
22 M 40  
46 M 45  
51 M 57  
58 M 32  
63 M 23  
73 F 58  
86 M 43  
132 F 66  
195 F 33  
214 M 50  
264 M 42  *Age at enrollment.
CA  cardiac arrest; ICD shock  appropriate implantable cardioverter-defibrillator intervention; N.A. deand backward elimination (likelihood ratio method). In all anal-
yses, inducibility proved to be nonsignificant and was removed in
backward analysis. All other covariates proved to be significant.
Results
Study population. A total of 308 patients were enrolled, and
their demographic profile is reported in Table 1. Patients had
a mean age at enrollment of 45  12 years; as expected
(3,6,11,13,14), most patients were men (n  247, 80%).
Diagnosis of BrS was established on the presence of a
type I ECG pattern in the absence of structural abnormal-
ities. Type I ECG was spontaneously present in 56% of
subjects (n  171), whereas in the remaining patients it was
induced upon intravenous drug challenge with ajmaline (1
mg/kg) or flecainide (2 mg/kg, max 150 mg) (Figs. 1A and
1B). The ECG parameters are presented in Table 1. QRS-f
(Fig. 1C) was present in 25 of 308 patients (8.1%). Genetic
analysis was performed in 123 patients and, in agreement
with previous findings (6,20), an SCN5A mutation was
identified in 20% of tested patients (n  24). Sixty-five
atients (21%) reported at least 1 syncopal spell in their
linical history, whereas 1 event occurred in 16 of 65
atients (25%). The first syncopal episode occurred an
verage of 2.92 years before enrollment (range 0 to 12
ears). Mean age at syncope was 45  13 years; none of the
patients experienced syncope before age 18.
At follow-up, 14 of 308 (4.5%) patients experienced
cardiac arrest (Fig. 1D) and/or documented ventricular
fibrillation: all patients were resuscitated (13 by the ICD,
and 1 by the emergency medical service); therefore, no
sudden death or permanent cerebral damage occurred in the
study. The clinical profile of the 14 patients with arrhythmic
events at follow-up is presented in Table 2.
PES and arrhythmic events at follow-up. Programmed
electrical stimulation was performed in all 308 patients; 126
of 308 patients (41%) met the criteria for inducibility
f
Inducibility
VRP
<200 ms QRS-f
SCN5A
Mutation Event Type
    ICD shock
    ICD shock
   N.A. ICD shock
    ICD shock
    ICD shock
    ICD shock
   N.A. ICD shock
   N.A. Resuscitated CA
   N.A. ICD shock
    ICD shock
   N.A. ICD shock
    ICD shock
    ICD shock
    ICD shocktory o
ncope













oxyribonucleic acid not available; SCD sudden cardiac death; other abbreviations as in Table 1.
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inducibility on the basis of the number of premature stimuli
delivered. All 308 patients were tested with a single prema-
ture extra-stimulus that induced arrhythmias in 7 of 308
(2.3%) patients; 2 premature stimuli were tested in 301
patients (the 7 patients inducible with 1 premature beat
were not further tested). Of 301 patients, 56 (19%) were
inducible with 2 premature beats. Finally, the 245 patients
who were not inducible with 1 or 2 premature beats
completed the protocol up to 3 extrastimuli, and 63 of 245
patients (26%) were inducible. Overall, of the 126 inducible
patients, 5.5% were induced with 1 premature beat, 44.5%
with 2 premature beats, and 50% with 3 premature beats. As
expected, the number of inducible patients is higher when
more aggressive protocols are used. No significant difference
in the duration of follow-up was present between inducible
and noninducible patients (35  16 vs. 37  16, p  0.4).
The site of inducibility was equally distributed between
right ventricular outflow tract (59 of 126: 46.8%) and right
ventricular apex (58 of 126; 46.0%): 9 (7.2%) patients were
inducible both from the outflow tract and the apex. Of 126
inducible patients, a second inducibility test was performed in
111 (88%) patients as part of the short-term reproducibility of
PES study elective protocol (see the Methods section). In
analogy with what we reported in 2002 (21), a reproducible
outcome of PES was achieved only in the minority of
patients (i.e., in 38 of 111 subjects [34%]) (Fig. 2).
An ICD was inserted in 98 of 126 (78%) inducible patients and
in 39 of 182 (21%) noninducible patients. It is possible that the
Figure 2 Reproducibility of VTs/VF Inducibility Study
in 111 Patients Enrolled in the PRELUDE Registry
Patients are divided in 3 groups according to the number of extra-stimuli
required for induction during the first inducibility study. Each dot represents
1 patient. Red dots indicate patients with reproducible results of inducibility
study, whereas blue dots represent patients with non-reproducible results of
inducibility study. Arrhythmia inducibility was reproducible in 1 of 7 (14%)
patients induced with a single premature beat, in 19 of 46 (41%) patients
induced with 2 premature beats, and in 18 of 58 (31%) patients induced with
3 premature beats. VTs/VF  sustained ventricular tachycardia/ventricular
fibrillation.medico-legal implications of nonimplanting patients who devel-oped VT/VF during PES influenced the physicians to recom-
mend an ICD for the inducible patients even if the protocol
allowed for a decision “not to implant.”
After a mean follow-up of 36  8 months (range 5 to 73
months), 14 events were observed in the 308 patients
(4.5%), corresponding to an annual event rate of 1.5%.
Kaplan-Meier survivorship analysis showed no statistical
difference in the outcome of inducible versus non-inducible
patients (5 arrhythmic events in 126 inducible subjects
[3.9%] vs. 9 arrhythmic events in 182 non-inducible pa-
tients [4.9%; log-rank 0.67]) (Fig. 3A, Table 3). Further-
more, when we restricted Kaplan-Meier survivorship anal-
ysis to the patients inducible with 1 and 2 premature stimuli,
we were similarly unable to demonstrate the ability of the
test to discriminate between patients with and those without
arrhythmic events at follow-up (log-rank p  0.89) (Fig. 3B,
Table 3).
The sensitivity and specificity of VTs/VF inducibility
with up to 3 premature beats to predict outcome were 35.7%
(95% confidence interval [CI]: 16% to 60%) and 58.8%
Figure 3 Survival According to VTs/VF Inducibility
Kaplan-Meier survivorship analysis of arrhythmic event-free survival according
to the presence/absence of sustained ventricular tachycardia/ventricular
fibrillation (VTs/VF) inducibility in the entire PRELUDE cohort (A) and in the
subgroup of patients inducible with 1 or 2 extrastimuli (B).
(
r
d electr
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patients inducible with 1 or 2 premature beats were ana-
lyzed, sensitivity and specificity of PES were 25% and
74.2%, respectively (Table 3).
Identification of other clinical predictors of arrhythmic
events. We performed univariate and multivariate analysis
to investigate whether other clinical variables are associated
with the occurrence of events at follow-up. We first ad-
dressed, on the basis of previous studies (6,8,14–17), the
univariate association with outcome of the following pre-
dictors: spontaneous type I ECG, history of syncope,
spontaneous type I ECG and syncope (combined endpoint
previously shown as the strongest predictor of arrhythmic
events at follow-up), PR duration, and QRS-f. We tested
the hypothesis—on the basis of the observations that
arrhythmic episodes in BrS are often initiated by a short-
coupled beat and that patients present with an abbreviated
action potential (22–24)—that the VRP might predict
arrhythmic risk (21). Sensitivity and specificity of clinical
variables to differentiate between patients with and without
events are presented in Table 3.
Kaplan-Meier analysis showed that history of syncope
log rank p  0.011) and spontaneous type I ECG (log-
ank p  0.004) (Figs. 4A and 4B), VRP (log-rank p 
0.002), and QRS-f (log-rank p  0.000001) (Fig. 5) were
significantly associated with outcome. Interestingly, as pre-
viously shown (6), the most powerful predictor of events was
the presence of syncope and of a spontaneous ECG pattern
(log-rank p  0.000105) (Fig. 6, Table 3).
We investigated the effect of each covariate (spontaneous
type I ECG, history of syncope, QRS-f, and VRP 200
ms) on VTs/VF inducibility. All covariates retained an
independent predictive value, whereas VT/VF inducibility
remained unable to predict events (Table 4). Hazard ratios
obtained with Cox multivariate analysis (stepwise analysis
with backward elimination, likelihood ratio method) when
all covariates were tested at the same time were as follows:
inducibility with up to 3 premature extrastimuli HR: 1.03
(95% CI: 0.34 to 3.16, p  0.96); spontaneous type I ECG
and history of syncope HR: 4.20 (95% CI: 1.38 to 12.79,
p 0.012); VRP200 ms HR: 3.91 (95% CI: 1.03 to 12.79,
p  0.045); QRS-f HR: 4.94 (95% CI: 1.54 to 15.8, p 
0.007). After inducibility was removed, significance of other
covariates remained the same, thus confirming redundancy
Prognostic Accuracy of Predictors of OutcomeTable 3 Prognostic Accuracy of Predictors of Outcome
Inducibility*
(Full Protocol)
Inducibility (With 1
or 2 Extra Stimuli)
Spontaneous T
ECG Patte
Sensitivity 35.7 (14–64) 25.0 (5.8–50) 92.9 (65–9
Specificity 58.8 (58–60) 74.2 (78–81) 45.7 (45–4
NNT 102.3 (20–200) — 14.5 (12–5
Univariate log-rank
(p value)
0.67 0.89 0.004
Values are % (95% confidence intervals). *Inducibility  inducibility of VTs/VF during programme
NNT number needed to treat; other abbreviations as in Table 1.of induction.We calculated the performance of each clinical indicator
of arrhythmic risk if used to guide the insertion of an ICD
and calculated the expected number of patients receiving
insertion to save 1 life (number needed to treat). The
number needed to treat values for each clinical variable were
as follows: 102.3 for inducibility, 12.4 for history of syncope,
14.5 for spontaneous ECG type I, 6.8 for the combined
History of
Syncope
Spontaneous Type 1
ECG and Syncope QRS-f VRP <200 ms
50.0 (25–76) 42.9 (19–69) 42.9 (20–69) 78.6 (49–94)
80.6 (79–82) 90.5 (89–92) 93.5 (92–95) 62.9 (62–64)
12.4 (6.7–108) 6.8 (3.7–26) 4.7 (2.7–14) 13.2 (9.4–50)
0.011 0.000105 0.000001 0.002
ical stimulation.
Figure 4 Survival According to Syncope
Before Enrollment and ECG Presentation
Kaplan-Meier survivorship analysis of arrhythmic event-free survival according
to (A) history of syncope before enrollment and (B) presence or absence of
spontaneous type 1 electrocardiogram (ECG).ype 1
rn
9)
7)
8)
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and 13.2 for VRP 200 ms (Table 3).
Discussion
Background. The most challenging aspect of BrS is repre-
sented by the lack of robust recommendations for the man-
agement of individuals presenting with the electrocardio-
graphic diagnosis of the disease without a previous
documentation of arrhythmias. The missing elements to for-
mulate recommendations for managing these patients are the
lack of agreement on the annual incidence of life-threatening
arrhythmias at follow-up (severity of the disease) and the
discordant opinions on the value of VTs/VF inducibility to
identify patients at higher risk of cardiac arrest.
Incidence of sudden death and role of VTs/VF inducibility
for risk stratification. The correct quantification of the an-
nual incidence of arrhythmic events in BrS patients is critical to
set indications for the prophylactic implant of a defibrillator. In
Figure 5 Survival According to Refractory Period and QRS-f
Kaplan-Meier survivorship analysis of arrhythmic event-free survival according
to presence or absence of (A) ventricular refractory period (VRP) 200 ms and
(B) QRS fragmentation (QRS-f).1998 Brugada et al. (25) reported no difference in the occur-rence of cardiac arrest at follow-up between symptomatic and
asymptomatic patients. In this first study they showed an
incidence of ventricular fibrillation and sudden death at
follow-up of 4.5%/year among previously symptomatic pa-
tients (80% had survived cardiac arrest) and of 2.7%/year
among asymptomatic patients (25). In the same study the
authors also reported inducibility at PES of 80% of patients
(78% in symptomatic and 85% in asymptomatic subjects).
In 2003, Brugada et al. (17) reported data in a cohort of 547
patients who had not experienced cardiac arrest (i.e., similar to
the patients prospectively followed in the PRELUDE registry)
over a mean follow-up of 24 months (range 1 to 160
months). Patients were studied with VTs/VF inducibility
protocol up to 3 premature extrastimuli (i.e., the same protocol
used in the PRELUDE registry). The inducibility rate was
40%, and the annual incidence of cardiac arrest/death was
4.1%. Interestingly, even though VTs/VF inducibility rate is
identical in the PRELUDE registry and in the 2003 study of
Brugada et al., the rate of events during follow-up is much
lower in the PRELUDE registry (1.5%/year in the
PRELUDE registry vs. 4.1%/year in Brugada et al. [17]). Even
more important, however, is the evidence that, despite the
similar rate of inducibility with the “3 premature beats”
protocol, the predictive value of the test was completely
different. Interestingly, both studies identified the presence of a
spontaneous pattern and the history of syncope as robust
prognostic indicators of events at follow-up; however, only the
study by Brugada et al. (17) suggested that inducibility at PES
is a most informative risk indicator, whereas it has no predictive
value in the PRELUDE registry. Remarkably when VTs/VF
inducibility was repeated, only 34% of inducible patients were
re-induced at the second trial (Fig. 2).
Figure 6 Survival According to Spontaneous Type 1 ECG
and History of Syncope
Kaplan-Meier survivorship analysis of arrhythmic event-free survival according
to the presence of spontaneous (Spont.) type 1 electrocardiogram (ECG) and
history of syncope.
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Brugada Syndrome: Results of the PRELUDE Registry December 27, 2011/January 3, 2012:37–45Data from the FINGER (France, Italy, the Netherlands,
Germany) study originated from pooling data from 11 Euro-
pean centers also provided information on rate of events and
inducibility in BrS (14). The study also included patients with
a history of cardiac arrest, but on the basis of reported data, we
were able to calculate the inducibility rate in the 967 enrolled
patients after the exclusion of individuals resuscitated from
ventricular fibrillation (i.e., the subgroup comparable to the
population of the PRELUDE registry). In the “no ventricular
fibrillation” subgroup of the FINGER study, the inducibility
rate with 3 premature stimuli was once more 40% and showed
no ability to predict life-threatening events at follow-up. In this
group of patients, the annual incidence of events was 1.1% (i.e.,
similar to that reported in the PRELUDE registry). A recent
study from Delise et al. (15) also addressed the same issue in a
population of patients who never experienced ventricular
tachycardia or ventricular fibrillation. The characteristics of
patients in the 2003 study by Brugada et al. (14,17) in Delise
(15) in the FINGER registry and in the PRELUDE popula-
tion are presented in Table 5.
Cox Multivariate ModelsTable 4 Cox ultivariate Models
p Valu
Independent effects
Inducibility 0.559
Spontaneous type 1 and syncope 0.001
Inducibility 0.835
Ventricular refractory period 0.008
Inducibility 0.972
QRS-fragmentation 0.000
Backward elimination—likelihood ratio
Step 1
Spontaneous type 1 and syncope 0.012
QRS-fragmentation 0.007
Ventricular refractory period 0.045
Inducibility 0.959
Step 2
Spontaneous type 1 and syncope 0.011
QRS-fragmentation 0.007
Ventricular refractory period 0.045
CI  confidence interval; HR  hazard ratio.
Comparison of Brugada Syndrome RegistriesTable 5 Comparison of Brugada Syndrome Registries
Brugada et al.
2003
n 547
Average follow-up (months) 24
Number of patients with syncope before enrollment (%) 124 (23%)
Spontaneous type 1 ECG (%) 391 (71%)
Arrhythmic events at follow-up 45 (8.2%
Annual arrhythmic event rate 4.1%
VTs/VF inducibility performed (%) 408 (75%)
Number of patients with inducible VTs/VF (%) 163 (40%)Values are n, n (%), or %. *Patients with sudden cardiac death have been excluded to allow comparison
FINGER  France, Italy, Netherlands, Germany study; PRELUDE  PRogrammed ELectrical stimUlationThe PRELUDE data provide a prospective evaluation of
the risk of cardiac arrest in BrS as well as an assessment of
the value of VT/VF inducibility to identify affected individ-
uals at high risk of sudden death. The annual rate of cardiac
arrest is 1.5% (i.e., much lower than what is consistently
reported by the registry of Brugada et al. [2,17]). Further-
more it is also evident by the results of the PRELUDE
registry that, irrespective of the protocol used, the VTs/VF
inducibility during PES is not useful to identify high-risk
patients in BrS (Table 3). Interestingly, using VTs/VF
inducibility to select patients for the implant, we would have
performed implantation in 126 individuals and observed an
arrhythmic event at 3 years of follow-up in 5 of them.
A new risk stratification scheme for BrS? The evidence
that VTs/VF inducibility is not a useful risk indicator opens
the need to establish alternative risk stratification metrics.
The robust predictive value of a spontaneous type I ECG and
history of syncope that we proposed in 2002 (6) and was
onfirmed by other groups (14,17) is once more supported in the
rospective evaluation of the PRELUDE registry, where it is
HR
95% CI
Lower Upper
0.721 0.241 2.159
6.406 2.211 18.558
0.890 0.298 2.661
5.666 1.578 20.346
1.020 0.337 3.091
8.898 3.040 26.038
4.198 1.378 12.788
4.928 1.540 15.776
3.908 1.030 14.824
1.030 0.336 3.155
4.205 1.382 12.791
4.902 1.560 15.402
3.903 1.030 14.786
FINGER (14)* PRELUDE
Delise et al. (15),
2011
967 308 320
32.5 36 40
313 (32%) 64 (21%) 105 (34%)
437 (45%) 171 (56%) 174 (54%)
29 (2.9%) 14 (4.5%) 17 (5.3%)
1.1% 1.5% 1.6%
602 (62%) 308 (100%) 245 (77%)
246 (41%) 126 (41%) 96 (39%)e(11),
)with the other studies.
preDictive valuE registry; other abbreviations as in Table 1.
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December 27, 2011/January 3, 2012:37–45 Brugada Syndrome: Results of the PRELUDE Registryassociated with4-fold increase (HR: 4.2) in the risk of having an
rrhythmic event as compared with patients without a spontane-
us type I ECG. Furthermore, having the ECG pattern un-
asked by a provocative drug test has a very high negative
redictive value that reflects the fact that only 1 patient without
pontaneous pattern had a cardiac arrest at follow-up (Table 2).
Interestingly, data from the PRELUDE registry identify 2
ovel clinical indicators of increased risk of life-threatening
vents: 1) the presence of QRS-f (16); and 2) the presence of
short VRP.
The idea of using QRS-f was based on the data by Morita
t al. (26), who suggested that—in an experimental model of
rS—fragmentation of QRS was a reliable indicator of sus-
eptibility to arrhythmias. The authors also tested in a pilot
linical study the value of this parameter in predicting arrhyth-
ic events and demonstrated that QRS-f but not VTs/VF
nducibility might be a good predictor of risk of events (16).
The results of the PRELUDE registry show that PES,
rrespective of the number of premature beats used, is not
redictive of arrhythmic events. The study confirms the
rognostic value of the presence of a spontaneous type I
CG and history of syncope and shows for the first time
hat QRS-f and a ventricular effective refractory period
200 ms are independent risk indicators in a large cohort of
atients prospectively investigated.
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